This content is restricted.
Brief
On 01/07/2025, the Italian Medicines Agency (AIFA) issued an update regarding AIFA Board approves reimbursement of two medicinal products. The board approved the reimbursement of Kapruvia (difelikefalin) for treating pruritus in adults with chronic kidney disease on dialysis and Prevymis (letermovir) for preventing CMV infection in immunocompromised patients post-transplant, extending its existing indications.
Highlights content goes here...
This content is restricted.
RADA.AI
Hello! I'm RADA.AI - Regulatory Analysis and Decision Assistance. Your Intelligent guide for compliance and decision-making. How can i assist you today?
Suggested